

LOUISIANA DRUG UTILIZATION REVIEW BOARD AGENDA

January 22, 2026, 3:00 PM, Baton Rouge, LA

The items on this discussion list apply to FFS and MCO unless otherwise noted.

Call to Order			Peggy Dean
Introductions			Peggy Dean
Review of September 10, 2025 Minutes			Peggy Dean
Louisiana ED Bridge Program Presentation			Dr. Vanessa de la Cruz
POS and Clinical Criteria Proposals (Vote Required)	1.	ORAL BUPRENORPHINE AGENTS – Increase maximum daily dose limit and modify quantity limits	Shawn Corley
	2.	ZURNAI® (nalmeferene) IM Autoinjector: New Formulation – Add age and quantity limit	Shawn Corley
	3.	ANZUPGO® (delgocitinib): New Drug – Add quantity limit and previous use of corticosteroids	Shawn Corley
	4.	SEPHIENCE™ (sepiapterin): New Drug – Add clinical criteria	Shawn Corley
	5.	EKTERLY® (sebetralstat): New Drug – Add clinical criteria	Shawn Corley
	6.	DAWNZERA™ (donidalorsen): New Drug – Add clinical criteria	Shawn Corley
	7.	EMPAVELI™ (pegcetacoplan): New Indication – Add quantity limit and expand acceptable diagnosis codes	Melissa Dear
	8.	WEGOVY® (semaglutide): New Indication (Injection) – Modify clinical criteria; New Formulation (Tablet) – Add clinical criteria, quantity limit, and therapeutic duplication	Melissa Dear
	9.	BRINSUPRI™ (brensocatic): New Drug – Add quantity limit and clinical criteria	Melissa Dear
	10.	KIRSTY™ (insulin aspart-xjhz): New Biosimilar – Add quantity limits	Melissa Dear
	11.	ELIQUIS® (apixaban) SPRINKLE/Tablet for Suspension: New Formulation – Add quantity limit for new dosage formulation	Melissa Dear
	12.	TYRUKO® (natalizumab-sztn): New Biosimilar – Add clinical criteria	Shawn Corley
	13.	EXXUA™ (gepirone): New Drug – Add quantity limit and clinical criteria	Shawn Corley
	14.	RHAPSIDO® (remibrutinib): New Drug – Add quantity limit and clinical criteria	Shawn Corley
	15.	ZANAFLEX® (tizanidine hydrochloride) 8 mg Capsule: New Dosage Strength – Add/update quantity limits; modify non-preferred criteria to include previous-use	Shawn Corley
	16.	JASCAYD® (nerandomilast): New Drug – Add quantity limit and clinical criteria	Shawn Corley
	17.	NYPOZI™ (filgrastim-txid): New Biosimilar – Add clinical criteria	Shawn Corley
	18.	ZORYVE™ (roflumilast) 0.3% Cream: Add previous use requirement	Shawn Corley
	19.	AVTOZMA® (tocilizumab-anoh): New Biosimilar – Add clinical criteria	Melissa Dear
	20.	TALTZ® (ixekizumab): P&T Changes – Modify existing clinical criteria	Melissa Dear
	21.	PREFERRED STELARA® (stekinumab) BIOSIMILARS: P&T Changes – Modify existing clinical criteria	Melissa Dear
Clinical Updates (No Vote Required)	22.	ACTEMRA® (tocilizumab): Expanded Indication – Modify existing clinical criteria to include expanded indication	Melissa Dear

	23.	OTEZLA® (apremilast) XR Tablets: New Dosage Formulation – Add new dosage formulation along with respective quantity limit to the clinical criteria	Melissa Dear
	24.	TREMFYA™ (guselkumab): Expanded Indication – Modify existing clinical criteria to include expanded age	Melissa Dear
	25.	SIMPONI® (golimumab): Expanded Indication – Modify existing clinical criteria to include expanded age	Melissa Dear
	26.	XELJANZ® (tofacitinib): Expanded Indication – Modify existing clinical criteria to include expanded age	Melissa Dear
	27.	HUMIRA® (adalimumab) BIOSIMILARS: AMJEVITA®, CYLTEZO®, HYRIMOZ®, YUFLYMA®, SIMLANDI® – Expanded Indications – Modify existing clinical criteria to include expanded ages	Melissa Dear
	28.	LEQVIO® (incisiran): Updated Indication – Modify existing clinical criteria to include updated indication	Shawn Corley
	29.	REPATHA® (evolocumab): New Indication – Modify existing clinical criteria to include new indication	Shawn Corley
	30.	EVKEEZA™ (evinacumab-dgnb): Expanded Indication – Modify existing clinical criteria to include expanded age	Shawn Corley
	31.	AJOVY™ (fremanezumab-vfrm): Expanded Indication – Modify existing clinical criteria to include expanded indication	Shawn Corley
	32.	KOSELUGO® (selumetinib): Expanded Indication and New Formulation – Modify existing clinical criteria to include expanded age and quantity limit for new formulation	Shawn Corley
	33.	VYJUVEK® (beremagene geperpavec-svdt): Expanded Indication – Modify existing clinical criteria to include expanded age	Melissa Dear
	34.	TEZSPIRE™ (tezepelumab-ekko): New Indication – Modify existing quantity limit and clinical criteria to include new indication	Melissa Dear
	35.	ZEPBOUND™ (tirzepatide): Modify existing clinical criteria based on provider input (<i>Implemented 1/1/2026</i>)	Melissa Dear
	36.	CASGEVY™ (exagamglogene autotemcel): Modify existing clinical criteria	Melissa Dear
RetroDUR	37.	LADUR Report	Megan Guidry
	38.	New Retrospective DUR Proposal	Megan Guidry